Activity of serotonin 5-HT1A receptor 'biased agonists' in rat models of Parkinson's disease and l-DOPA-induced dyskinesia

Neuropharmacology

Volumn 93, Issue , 2015, Pages 52-67

  Iderberg, H ^a   McCreary, A C ^b   Varney, M A ^c   Cenci, M A ^a   Newman Tancredi, A ^c  

^a LUND UNIVERSITY   (Sweden)

^b CHARLES RIVER LABORATORIES   (United States)

^c NEUROLIXIS INC   (United States)

Author keywords

5 HT; 5 HT1A receptor; 6 OHDA rat model of PD; Biased agonist; Dopamine serotonin; l DOPA; l DOPA Induced dyskinesia; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; F 13714; F 15599; GLUTAMIC ACID; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A AGONIST; SEROTONIN RECEPTOR; TANDOSPIRONE; UNCLASSIFIED DRUG; 3-CHLORO-4-FLUOROPHENYL-(4-FLUORO-4-(((5-METHYLPYRIMIDIN-2-YLMETHYL)AMINO)METHYL)PIPERIDIN-1-YL)METHANONE; ADRENERGIC RECEPTOR STIMULATING AGENT; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIPARKINSON AGENT; OXIDOPAMINE; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN; SEROTONIN 1 AGONIST; SEROTONIN 1A RECEPTOR; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; CIRCLING BEHAVIOR; CONTROLLED STUDY; CYLINDER TEST; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; DYSKINESIA; FEMALE; FORELIMB; IN VIVO STUDY; LOCOMOTION; MICRODIALYSIS; MOTOR COORDINATION; NONHUMAN; PARKINSON DISEASE; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; RAT; ROTAROD TEST; SEROTONIN RELEASE; TASK PERFORMANCE; ANIMAL; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; MALE; METABOLISM; MOTOR ACTIVITY; PSYCHOMOTOR PERFORMANCE; SPRAGUE DAWLEY RAT;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MALE; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; OXIDOPAMINE; PARKINSON DISEASE; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; TYROSINE 3-MONOOXYGENASE;

EID: 84922741840     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.01.012     Document Type: Article

References (73)

1. T. Antonelli Effects of sarizotan on the corticostriatal glutamate pathways Synapse 58 2005 193 199
2. P. Armitage, G. Berry, and J.N.S. Matthews Statistical Methods in Medical Research 2001 Blackwell Science Malden, MA
3. 1A agonist, F13714: a microdialysis study in the rat Br. J. Pharmacol. 149 2006 170 178
4. E. Bezard Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia Mov. Disord. 28 2013 1088 1096
5. V. Bonifati Buspirone in levodopa-induced dyskinesias Clin. Neuropharmacol. 17 1994 73 82
6. L.S. Breger, S.B. Dunnett, and E.L. Lane Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat Neurobiol. Dis. 50 2013 142 150
7. 1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase Eur. J. Pharmacol. 534 2006 63 70
8. T. Carlsson Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease J. Neurosci. Off. J. Soc. Neurosci. 27 2007 8011 8022
9. M. Carta Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain J. Neurol. 130 2007 1819 1833
10. M. Carta Involvement of the serotonin system in L-dopa-induced dyskinesias Park. Relat. Disord. 14 Suppl. 2 2008 S154 S158
11. M.A. Cenci, C.S. Lee, and A. Bjorklund L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10 1998 2694 2706
12. M.A. Cenci, K.E. Ohlin, and P. Odin Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease CNS Neurol. Disord. Drug Targets 10 2011 670 684
13. 2A receptors are increased in Parkinson's disease neocortex Ann. N. Y. Acad. Sci. 861 1998 288 289
14. G. Chinaglia Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram Neuroscience 54 1993 691 699
15. A. Dekundy Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model Behav. Brain Res. 179 2007 76 89
16. K.B. Dupre Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats Exp. Neurol. 229 2011 288 299
17. K.L. Eskow The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy Pharmacol. Biochem. Behav. 87 2007 306 314
18. K.L. Eskow The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats Synapse 63 2009 610 620
19. S. Fahn The history of dopamine and levodopa in the treatment of Parkinson's disease Mov. Disord. Off. J. Mov. Disord. Soc. 23 Suppl. 3 2008 S497 S508
20. A. Fletcher Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist Behav. Brain Res. 73 1996 337 353
21. J. Garcia Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia Neurobiol. Dis. 43 2011 576 587
22. S. Gil The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced dyskinesia in a hemiparkinsonian rat model Cell. Mol. Neurobiol. 30 2010 817 825
23. C.G. Goetz Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov. Disord. Off. J. Mov. Disord. Soc. 22 2007 179 186
24. 1A and 5-HT2 receptor and alpha 2-adrenoceptor mediated function in mice Psychopharmacol. Berl. 90 1986 482 487
25. L. Gregoire Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys Park. Relat. Disord. 15 2009 445 452
26. G.M. Halliday Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease Brain Res. 510 1990 104 107
27. G.M. Halliday Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease Ann. Neurol. 27 1990 373 385
28. A. Hamik Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites Biol. Psychiatry 28 1990 99 109
29. M.A. Hely Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years Mov. Disord. Off. J. Mov. Disord. Soc. 20 2005 190 199
30. P. Huot, S.H. Fox, and J.M. Brotchie The serotonergic system in Parkinson's disease Prog. Neurobiol. 95 2011 163 212
31. P. Huot Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? J. Pharmacol. Exp. Ther. 339 2011 2 8
32. M.M. Iravani In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability J. Pharmacol. Exp. Ther. 319 2006 1225 1234
33. C.A. Jones An in vivo pharmacological evaluation of pardoprunox (SLV308)-a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease Eur. Neuropsychopharmacol. 20 2010 582 593
34. 1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease No To Shinkei 54 2002 133 137
35. T. Kenakin Functional selectivity and biased receptor signaling J. Pharmacol. Exp. Ther. 336 2010 296 302
36. 1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential Eur. J. Pharmacol. 420 2001 103 112
37. H.S. Lindgren L-DOPA-induced dopamine efflux in the striatum and the substantia Nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J. Neurochem. 112 2010 1465 1476
38. L. Llado-Pelfort Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors Br. J. Pharmacol. 160 2010 1929 1940
39. 1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons Cereb. Cortex 22 2012 1487 1497
40. M. Lundblad Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur. J. Neurosci. 15 2002 120 132
41. M. Lundblad, E. Vaudano, and M.A. Cenci Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia J. Neurochem. 84 2003 1398 1410
42. 1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions Brain Res. 1112 2006 126 133
43. 1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease Psychopharmacol. Berl. 192 2007 49 59
44. L.J. Mignon, and W.A. Wolf 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease Neuroreport 16 2005 699 703
45. C. Miguelez Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease Front. Neural Circuits 8 2014 21
46. J.N. Murthy, and M.R. Pranzatelli Brainstem 5-hydroxytrytamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat: myoclonus and other serotonergic behaviors J. Recept. Res. 12 1992 287 297
47. A. Nahimi Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning J. Neurochem. 120 2012 806 817
48. 1A receptor agonists and the atypical antipsychotics clozapine and S16924 Naunyn Schmiedeb. Arch. Pharmacol. 368 2003 188 199
49. 1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia Int. J. Neuropsychopharmacol. 8 2005 341 356
50. 1A receptor agonist Br. J. Pharmacol. 156 2009 338 353
51. 1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders Neuropsychiatry 1 2011 149 164
52. 1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice J. Pharmacol. Sci. 109 2009 593 599
53. C.W. Olanow Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study) Clin. Neuropharmacol. 27 2004 58 62
54. C.W. Olanow Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease Mov. Disord. 28 2013 1064 1071
55. 1A receptor stimulation Neuropharmacology 61 2011 753 760
56. P.J. Pauwels Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins Biochem. Pharmacol. 61 2001 1079 1092
57. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 2007 Academic Press
58. S.J. Peroutka Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors Biol. Psychiatry 20 1985 971 979
59. M. Politis Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients J. Clin. Invest. 124 2014 1340 1349
60. 1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy Behav. Pharmacol. 11 2000 299 305
61. D. Rylander Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling J. Pharmacol. Exp. Ther. 330 2009 227 235
62. D. Rylander A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys Neurobiol. Dis. 39 2010 352 361
63. D. Rylander Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Ann. Neurol. 68 2010 619 628
64. N. Santana Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex Cereb. Cortex 14 2004 1100 1109
65. B. Scatton Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease Brain Res. 275 1983 321 328
66. E. Shin Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease Neurobiol. Dis. 47 2012 393 406
67. E. Shin The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation Neurobiol. Dis. 62 2014 233 240
68. H. Tanaka Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats Neuroreport 10 1999 631 634
69. Y. Tani Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats Eur. J. Pharmacol. 649 2010 218 223
70. J.E. Westin Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia J. Neurosci. Off. J. Soc. Neurosci. 26 2006 9448 9461
71. C. Winkler L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 10 2002 165 186
72. B.Y. Zeng Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia Neurobiol. Dis. 40 2010 599 607
73. Z.T. Zhu Modulation of medical prefrontal cortical D1 receptors on the excitatory firing activity of nucleus accumbens neurons elicited by (-)-Stepholidine Life Sci. 67 2000 1265 1274